17Q1 Stock Chart & Stats
€2.56
-€0.04(-2.45%)
At close: 4:00 PM EST
€2.56
-€0.04(-2.45%)
Day’s Range― - ―
52-Week Range€1.60 - €3.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.28B
Enterprise Value€39.54K
Total Cash (Recent Filing)€2.97B
Total Debt (Recent Filing)€7.08B
Price to Earnings (P/E)51.2
Beta0.74
Next Earnings
Aug 20, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.63Price Target Upside41.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.14
Revenue Forecast (FY)€2.09B
Bulls Say, Bears Say
Bulls Say
Integrated CRDMO ModelPharmaron's integrated fee-for-service CRDMO model creates durable cross-selling opportunities across discovery, development and manufacturing. End-to-end capabilities increase client stickiness, support multi-year master agreements, and smooth revenue mix over time versus single-service peers.
Low Leverage / Resilient Balance SheetA low debt-to-equity ratio (~0.23) and growing shareholders' equity provide financial flexibility for capacity investment, working capital needs, or selective M&A. This reduces refinancing and solvency risk, supporting long-term operational continuity through industry cycles.
Healthy Operating MarginsSustained net and EBIT margins near 12%-15% indicate the business retains pricing power and operational efficiency across technical services and manufacturing. Persistent profitability supports reinvestment in capacity and R&D infrastructure and underpins long-term return generation.
Bears Say
Weak Cash ConversionOperating cash flow covers only ~39% of net income and FCF dropped materially year-over-year, signalling earnings quality and working-capital timing issues. Persistent weak cash conversion limits internal funding for capex/dividends and increases reliance on external financing, raising long-term risk.
Slowing Revenue GrowthTTM revenue growth decelerated to roughly 3.2%, a marked slowdown from prior periods. For a services provider, sustained top-line weakness can reflect tougher project wins, competitive pricing pressure, or lower utilization, reducing visibility on scaling and future margin recovery.
Margin Compression Vs. Prior PeakMaterial margin compression since 2021 suggests structural pressures—higher input costs, pricing erosion, or unfavorable service mix. If persistent, margin erosion undermines return on capital and the firm's ability to reinvest profitably, threatening long-term profitability resilience.
Pharmaron Beijing Co., Ltd. Class H News
17Q1 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was €1.60 and its highest was €3.32 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is €10.28B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2026 which is in 3 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported €0.023 earnings per share for the quarter, missing the consensus estimate of €0.026 by -€0.003.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H does not currently pay dividends.
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.03.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of €0.023 in its last earnings report, missing expectations of €0.026. Following the earnings report the stock price went up 6.404%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in DE:17Q1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
0.79%
Trailing 12-Months
Asset Growth
15.52%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
17Q1 Stock 12 Month Forecast
Average Price Target
€3.63
▲(41.78% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―